AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 791971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine paste used for 4 weeks
Number of subjects: 0
Study 791971 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental paste used for 8 weeks
Number of subjects: 0
Study 791971 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 0
Study 31307434 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP lifestyle intervention programme (12 weeks) followed by 9 months of monthly follow-up appointments
Number of subjects: 150
Study 31307434 — intervention group
Group type: COMPARATOR
Intervention: Usual ongoing diabetes care
Number of subjects: 150
Study 28195844 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 nm red LEDs
Number of subjects: 52
Study 28195844 — intervention group
Group type: COMPARATOR
Intervention: 411 to 777 nm white LEDs
Number of subjects: 52
Study 24664189 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 147
Study 24664189 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 147
Study 24664189 — intervention group
Group type: EXPERIMENTAL
Intervention: NND compliance
Number of subjects: 147
Study 24664189 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 147
Study 23318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective testing (D-dimer testing for outpatients with low or moderate clinical pretest probability (C-PTP) and venous ultrasonography without D-dimer testing for high C-PTP and inpatients)
Number of subjects: 1723
Study 23318311 — intervention group
Group type: COMPARATOR
Intervention: Uniform testing (D-dimer testing for all participants)
Number of subjects: 1723
Study 23318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective testing
Number of subjects: 1723
Study 21682578 — intervention group
Group type: COMPARATOR
Intervention: Sun protection advice via letter
Number of subjects: 316
Study 21682578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection advice via personal GP consultation (Group 2)
Number of subjects: 316
Study 21682578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection advice via personal GP consultation with phototest (Group 3)
Number of subjects: 316
Study 19467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Point vibration - ultrasonic vibration applied to the core surface for 5 s on each face, totaling 25 s
Number of subjects: 60
Study 19467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate vibration - intermittent application of ultrasonic vibration for 10 s to the labial and lingual surfaces, 10 s to the mesial and distal surfaces, and 5 s to the incisal surface, totaling 25 s
Number of subjects: 60
Study 19467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 - core with 5 mm diameter/height and post diameter of 1.3 mm
Number of subjects: 60
Study 19467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 - core with the same diameter as the post (1.3 mm) and height of 5 mm
Number of subjects: 60
Study 19467051 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 - core with the same diameter as the post (1.3 mm) and height of 3 mm
Number of subjects: 60
Study 16522295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive stop‐smoking intervention six to eight weeks before surgery
Number of subjects: 120
Study 16522295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 15141412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump-assisted feeding (G1)
Number of subjects: 100
Study 15141412 — intervention group
Group type: COMPARATOR
Intervention: Gravity-controlled feeding (G2)
Number of subjects: 100
Study 10674470 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative serum Ig levels in brain tumours and LDDs
Number of subjects: 227
Study 10674470 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative serum IgG levels
Number of subjects: 227
Study 10674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative serum IgA levels in patients with acoustic neurinoma
Number of subjects: 227
Study 10674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative serum IgM levels in patients with acoustic neurinoma
Number of subjects: 227
Study 10674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative serum IgG, IgA, and IgM levels in patients with meningioma
Number of subjects: 227
Study 10674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative serum IgG and IgM levels in patients with glioma
Number of subjects: 227
Study 10674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative serum IgA and IgM levels in patients with LDD
Number of subjects: 227
Study 9308510 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (1.3 mg, 2 inhalations every 4 hours while awake for 1 week)
Number of subjects: 15
Study 9308510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 inhalations every 4 hours while awake for 1 week)
Number of subjects: 15
Study 8345592 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 110
Study 8345592 — intervention group
Group type: COMPARATOR
Intervention: Ureteral manipulation before ESWL
Number of subjects: 110
Study 8345592 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ ESWL
Number of subjects: 110
Study 3732093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25‐50 mg daily)
Number of subjects: 0
Study 3732093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3732093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 30872075 — intervention group
Group type: EXPERIMENTAL
Intervention: High cutoff haemodialysis (HCO‐HD)
Number of subjects: 90
Study 30872075 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HF‐HD)
Number of subjects: 90
Study 30049811 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for PET- patients, 2 cycles followed by 2 more cycles after negative PET.
Number of subjects: 149
Study 30049811 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) plus 3060-cGy involved-field RT for PET+ patients, 2 cycles after positive PET.
Number of subjects: 149
Study 26716656 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of encapsulated Cassia cinnamon bark (CASS)
Number of subjects: 10
Study 26716656 — intervention group
Group type: COMPARATOR
Intervention: 5 g of encapsulated placebo (PLC)
Number of subjects: 10
Study 24574351 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 59
Study 24574351 — intervention group
Group type: EXPERIMENTAL
Intervention: ObeseND
Number of subjects: 59
Study 24574351 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 22735863 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/day for six months)
Number of subjects: 33
Study 22735863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g/day of maltodextrin for six months)
Number of subjects: 33
Study 22735863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CRE and PLA)
Number of subjects: 33
Study 19262361 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal standard heart failure therapy
Number of subjects: 99
Study 17638076 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional hazards mixed‐effects model (PHMM)
Number of subjects: 0
Study 17638076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized covariate residuals
Number of subjects: 0
Study 12734897 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief supportive‐expressive group psychotherapy
Number of subjects: 124
Study 12734897 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 124
Study 11052282 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoComb H (haemostyptic)
Number of subjects: 30
Study 11052282 — intervention group
Group type: COMPARATOR
Intervention: Compresses (control)
Number of subjects: 30
Study 9231199 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of DEC
Number of subjects: 71
Study 9231199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 8330600 — intervention group
Group type: EXPERIMENTAL
Intervention: subarachnoid bupivacaine plus epidural morphine and bupivacaine
Number of subjects: 200
Study 8330600 — intervention group
Group type: COMPARATOR
Intervention: subarachnoid bupivacaine
Number of subjects: 200
Study 8330600 — intervention group
Group type: COMPARATOR
Intervention: subarachnoid bupivacaine plus intravenous midazolam and buprenorphine
Number of subjects: 200
Study 8330600 — intervention group
Group type: COMPARATOR
Intervention: epidural bupivacaine
Number of subjects: 200
Study 8330600 — intervention group
Group type: COMPARATOR
Intervention: epidural bupivacaine plus epidural morphine
Number of subjects: 200
Study 3033040 — intervention group
Group type: EXPERIMENTAL
Intervention: Local antimicrobial prophylaxis (50 mg of polymyxin B, 80 mg of gentamicin, 300 mg of amphotericin B)
Number of subjects: 39
Study 3033040 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 39
Study 30145098 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine
Number of subjects: 47366
Study 30145098 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis vaccines
Number of subjects: 47366
Study 25986159 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated honey (53.5 g daily for 40 days)
Number of subjects: 12
Study 25986159 — intervention group
Group type: COMPARATOR
Intervention: Control (non-formulated kanuka honey)
Number of subjects: 12
Study 25509258 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Qizhu Granule (CQG) plus Lamivudin (LAM) and Adefovir (ADV)
Number of subjects: 103
Study 22287641 — intervention group
Group type: EXPERIMENTAL
Intervention: Early passive motion exercises conducted 3 to 4 times per day during the abduction brace‐wearing period.
Number of subjects: 105
Study 22287641 — intervention group
Group type: COMPARATOR
Intervention: No passive motion allowed during the same period.
Number of subjects: 105
Study 20356588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 0
Study 20356588 — intervention group
Group type: COMPARATOR
Intervention: Excision
Number of subjects: 0
Study 18257772 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 54
Study 16178481 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mupirocin cream applied daily to the exit site
Number of subjects: 40
Study 16178481 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study 12955869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation (HFES) at 50 Hz, 15 s on, 45 s off, intensity 100 mA
Number of subjects: 7
Study 10812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-bath with essential oil of lavender
Number of subjects: 0
Study 10812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-bath without essential oil of lavender
Number of subjects: 0
Study 8853261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrease HL (25,000 units of lipase per capsule, 3 capsules/day)
Number of subjects: 25
Study 8853261 — intervention group
Group type: COMPARATOR
Intervention: Creon (8000 units of lipase per capsule, 9 capsules/day)
Number of subjects: 25
Study 8853261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrease HL with omeprazole (20 mg/day)
Number of subjects: 25
Study 8853261 — intervention group
Group type: COMPARATOR
Intervention: Creon with omeprazole (20 mg/day)
Number of subjects: 25
Study 1737543 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 95
Study 1737543 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose minimization
Number of subjects: 95
Study 1737543 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 95
Study 1737543 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR3 and -DR4 status
Number of subjects: 95
Study 6439298 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled medically and socially preventive intervention (home visits every three months)
Number of subjects: 285
Study 6439298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scheduled intervention, visited during the final three months)
Number of subjects: 285
Study 6439298 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled medically and socially preventive intervention
Number of subjects: 285
Study 6439298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 30920584 — intervention group
Group type: COMPARATOR
Intervention: Intra-procedural only bivalirudin infusion
Number of subjects: 137
Study 30920584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged bivalirudin infusion
Number of subjects: 137
Study 30244844 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50mg, 150mg, or 300mg subcutaneously)
Number of subjects: 30
Study 30244844 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 30
Study 30244844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27283364 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) 500 mg/day for 5 days
Number of subjects: 60
Study 27283364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 24670120 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PROT beverage given 30 and 5 min prior to, at the 15 min mark during, immediately after, and 30 min after downhill running (360 kilocalories total in T1)
Number of subjects: 9
Study 24670120 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PROT beverage given immediately after and 30 min after downhill running (isocaloric amount in T2)
Number of subjects: 9
Study 24670120 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage given at all time points
Number of subjects: 9
Study 22278391 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained handcyclists
Number of subjects: 20
Study 22278391 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained handcyclists at 50 W
Number of subjects: 20
Study 22278391 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained handcyclists at 80 W
Number of subjects: 20
Study 18835953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (n = 19,326)
Number of subjects: 38716
Study 18835953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19,390)
Number of subjects: 38716
Study 17786067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days
Number of subjects: 909
Study 17786067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 909
Study 17786067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 909
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy regimen including amoxicillin and clarithromycin with omeprazole, lansoprazole, or rabeprazole
Number of subjects: 249
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizers in normal acid secretion IL-1beta genotype group
Number of subjects: 249
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 homozygous in normal acid secretion IL-1beta genotype group
Number of subjects: 249
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 heterozygous in normal acid secretion IL-1beta genotype group
Number of subjects: 249
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low acid secretion IL-1beta genotype group
Number of subjects: 249
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin susceptibility
Number of subjects: 249
Study 14638340 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype status
Number of subjects: 249
Study 10826574 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical intrauterine instillation of 5 mL of 2% lignocaine
Number of subjects: 90
Study 10826574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8865110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptide-containing solution (glycyl-glutamine/glycyl-tyrosine) infused at 0.60 mL/h/kg; 82.2 mg total dipeptides/amino acids/h/kg
Number of subjects: 15
Study 8865110 — intervention group
Group type: COMPARATOR
Intervention: Conventional amino acid solutions infused at 0.73 mL/h/kg; 83.2 mg total amino acids/h/kg
Number of subjects: 15
Study 1633724 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin (75 mg)
Number of subjects: 30
Study 1633724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6338800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate intravenously prior to induction of anaesthesia
Number of subjects: 60
Study 6338800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethamsylate)
Number of subjects: 60
Study 31064361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1544
Study 31064361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1544
Study 31064361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1544
Study 28168513 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR participants
Number of subjects: 92
Study 28168513 — intervention group
Group type: COMPARATOR
Intervention: CMR drop-outs
Number of subjects: 92
Study 26415738 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention group received the CPD outcomes framework and associated training.
Number of subjects: 48
Study 26415738 — intervention group
Group type: COMPARATOR
Intervention: Control group received information on new CPD requirements through the post.
Number of subjects: 48
Study 26415738 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention group with rewritten records.
Number of subjects: 48
Study 22465984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity training
Number of subjects: 19
Study 22465984 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 19
Study 21958928 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-reminded group (received a memory card with a video clip about CPR and AED use)
Number of subjects: 75
Study 21958928 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-reminded group
Number of subjects: 75
Study 19430350 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 291
Study 19430350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 291
Study 19430350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of losartan and nebivolol
Number of subjects: 291
Study 19430350 — intervention group
Group type: COMPARATOR
Intervention: Losartan and Nebivolol
Number of subjects: 291
Study 16963731 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 or 500 mg/d)
Number of subjects: 70
Study 16963731 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study 16831672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (68 patients)
Number of subjects: 139
Study 16831672 — intervention group
Group type: COMPARATOR
Intervention: Steroid (71 patients)
Number of subjects: 139
Study 9895078 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 1% lidocaine
Number of subjects: 20
Study 9895078 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lidocaine
Number of subjects: 20
Study 8840367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers, digoxin, and beta-blockers (specific dosages and duration not provided)
Number of subjects: 0
Study 2000267 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced education program (lectures and handouts)
Number of subjects: 0
Study 2000267 — intervention group
Group type: COMPARATOR
Intervention: Risks-only (negative or 'scare tactics') presentation
Number of subjects: 0
Study 6133056 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy with chloroquine (10 mg base/kg)
Number of subjects: 54
Study 6133056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapeutic regimen of chloroquine (25 mg base/kg)
Number of subjects: 54
Study 6133056 — intervention group
Group type: COMPARATOR
Intervention: In-vitro testing of chloroquine resistance
Number of subjects: 54
Study 30929491 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant Removal (IR)
Number of subjects: 179
Study 29741133 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-coated components
Number of subjects: 60
Study 29741133 — intervention group
Group type: COMPARATOR
Intervention: Uncoated components
Number of subjects: 60
Study 27485577 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-detection interval (LDI)
Number of subjects: 220
Study 27485577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tachycardia pacing (ATP)
Number of subjects: 220
Study 24357853 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTRP9 concentrations
Number of subjects: 221
Study 22609423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (100 cc, three times a week for 1 year)
Number of subjects: 101
Study 22609423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 101
Study 22609423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 20638818 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (5-fluorouracil)
Number of subjects: 63
Study 20638818 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP (cisplatin)
Number of subjects: 63
Study 20638818 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + CDDP
Number of subjects: 63
Study 20638818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 63
Study 18402856 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling and educational leaflets in the postnatal ward after delivery
Number of subjects: 600
Study 18402856 — intervention group
Group type: COMPARATOR
Intervention: No formal contraceptive advice (Control group)
Number of subjects: 600